Login to Your Account



Other News To Note


Tuesday, December 11, 2012
• Cell Therapeutics Inc., of Seattle, said its board approved certain amendments to the firm's existing shareholder rights plan to decrease the exercise price of the preferred stock purchase rights from $14 to $8 and to extend the final expiration date from the close of business on the third anniversary of Jan. 7, 2010, to the close of business on Dec. 3, 2015.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription